Table 2.
Details of treatment condition.
| Study (Publication Year) | SSNHL Definition | Drug |
Mode of administration |
Duration fo Treatment |
Dose and Frequency |
adjuvant therapy |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| T | C | T | C | T | C | T | C | T | C | ||
| [1]Chen, 2018 | At least 20 dB hearing lossin 2 CFs occurring within 3 days | MP | MP | auripuncture injection | IV | 10d | NA | 0.5~0.7 mL/d every other day for 5 times | 40 g/L:8mg/(kg·d);reduced and stopped gradually after 6 days | all patients received vasodilators and neurotrophic agents | |
| [2]Gülce et al., 2017 | At least 20 dB hearing lossin 3 CFs occurring within 3 days | DEX | P | auripuncture injection | oral | 6d | NA | 8mg/2 mL, 0.5–0.7 cc, 3 times every other day | 1 mg/kg (maximum 80 mg) and tapering 10 mg every 3 days | All patients received the standard treatment protocol of our institu_×005f tion for SSHL; intravenous low molecular weight dextran (5 cc/kg) for 5–10 days, an oral diuretic agent (acetazola mide) for a month, an oral antiviral agent (acyclovir) for 5 days, an oral vasodilator agent (betahistine), and an oral cytoprotective agent (trimetazidine) for 3 months. | |
| [3]Hong et al., 2009 | At least 20 dB hearing lossin 3 CFs occurring within 3 days | DEX | P | auripuncture injection | oral | 8d | 8d | 5 mg/mL, 0.3–0.4 cc once a day | 60 mg for 4 days followed by 40 mg for 2 days and 20 mg for 2 days | treating with other medications, such as a peripheral vasodilator and ginkgo biloba extract | |
| [4]Liang et al., 2012 | At least 20 dB hearing lossin 2 CFs occurring within 3 days | DEX | P | Eustachian tube injection | IV/oral | 10d | 37d | 5 mg/mL, every other day for 5 times | IV:10 mg/d DX for 7 days and followed by oral P 30 mg/d, reduce 5 mg every 7 days | intravenous Ginato 87.5 mg/d for 14 days and | |
| [5]LI Hui et al., 2013 | At least 20 dB hearing lossin 2 CFs occurring within 3 days | DEX | DEX | auripuncture injection | IV | 10d | 14d | 5 mg/mL, 1 mL/d once a day | 10 mg/d for 7 days, halve the dosage for another 7 days | IV:shuxuening injection 20 mL/d and Vinpocetine 30 mg/d; intramuscular injection: Vitamin1 0.1 g/d and Vitamin12 0.5 mg/d for 2 weeks | |
| [6]Lim, 2013 | At least 20 dB hearing lossin 3 CFs occurring within 3 days | DEX | P | auripuncture injection | oral | 14d | 10d | 5 mg/mL,0.3–0.4 mL, twice a week for 2 weeks, for a total of 4 times | 60 mg/d for 5 days,40 mg/d for 2 days,20 mg/d for 2 days, and 10 mg/d for 1 day | NA | |
| [7]LI Zhi et al., 2015 | At least 20 dB hearing lossin 2 CFs occurring within 3 days | Steroids | auripuncture injection | oral | 10d | 10d | 5 mg/mL, every other day for 5 times | 1mg/(kg·d) | all patients received vasodilators and neurotrophic agents | ||
| [8]Michael, 2018 | At least 20 dB hearing lossin 3 CFs occurring within 3 days | MP | P | auripuncture injection | IV/oral | 10d | 17d | 62.5 mg/mL, 0.4–0.6 mL every day for 1, 3, 5, 10 days after presentation(total of 4 times) | IV,P 1 mg/(kg·d)for 7 days followed by 0.5mg/(kg·d)for another 3 days;then oral MP:32 mg/d for 4 days followed by oral MP 16 mg/d for another 3 days | NA | |
| [9]Peng et al., 2008 | At least 20 dB hearing lossin 2 CFs occurring within 3 days | DEX | DEX | auripuncture injection | oral | 10d | 10d | 5 mg/d, once a day for 10 times | 0.75mg × 3/d for 7 dyas and 0.75 × 2 for another 2 days | IV:Low molecular dextran 500 mL, buflomedil 0.2g, intramuscular injection: Vitamin1 0.1 g/d and Vitamin12 0.5 mg/d for 10d or 20d | |
| DEX | DEX | Eustachian tube injection | IV | 10d | 10d | 5 mg/d for 10 times | 10 mg for 4 days and halve the dosage for another 6 days | ||||
| [10]Qu et al., 2015 | NA | MP | MP | auripuncture injection | IV | 10d | 7d | 40 mg/d every other day for 10 days | 80 mg/d for 4 days and reduced to 40 mg/d for another 3 days | all patients received vasodilators and neurotrophic agents | |
| [11]Tang et al., 2015 | NA | DEX | DEX | auripuncture injection | IV | 12d | 6d | 5 mg/d every 3 day for 4 times | 10 mg/d for 3 days and halve the dosage for another 3 days | IV:Cinepazide maleate 240 mg/d, ginkgo leaf extract and dipyridamole 30 mL/d, mecobalamin 0.5 mg/d;Oral:flururizine gum capsule,5 mg/d for 10 days | |
| [12]Zhang et al., 2016 | At least 20 dB hearing lossin 2 CFs occurring within 3 days | MP | P | auripuncture injection | oral | 7d | 7/14d | 0.4–1 mL/d, 7 times of treatment | 60 mg/d for 4 days, reduce 10 mg every 2 days to stop drug | IV:Ginaton 105 mg/d for 7 days or 14 days | |
| [13]Rauch, 2011 | hearing loss with onset in less than 72 h | MP | P | auripuncture injection | oral | 2W | 19d | 40 mg/mL every 3–4 days for 1 times | 60 mg/d for 14 days, followed by a 5-day taper(50 mg, 40 mg, 30 mg, 20 mg and to 10 mg) | NA | |
| [14]Kosyakov et al., 2011 | At least 20 dB hearing lossin 3 CFs occurring within 3 days | DEX | DEX | auripuncture injection | IV | 6M | 10d | 4cc for 10 days, 4 mg/d for 20 days and 4 mg 2 times a week over 5 months | 0.1mg/(kg·d) | NA | |
| [15]Dispenza et al., 2011 | At least 20 dB hearing lossin 3 CFs occurring within 3 days | P | DEX | auripuncture injection | oral | 4W | 14d | 4 mg/mL weekly for a total of four injections | 60 mg tapered | NA | |
T, Treatment group C, control group NA, not available MP, Methylprednisolone P, prednisone DEX, dexamethasone M, month d, day CF, continuous frequency PTA, pure tone average.